Lilly to push ahead on inhaled insulin
Eli Lilly and Co. today said it would plow ahead with plans to develop an inhaled insulin product even as competitor Pfizer Inc. announced it would stop making its poor-selling Exubera version. Lilly President and Chief Operating Officer made the comment while discussing the Indianapolis drugmaker’s third-quarter results. Profit was up 6 percent, to $926.3 […]